{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:32:27Z","timestamp":1793835147214,"version":"4.6.1"},"reference-count":280,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373191"],"award-info":[{"award-number":["82373191"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U25C2043"],"award-info":[{"award-number":["U25C2043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2025ZD0544400"],"award-info":[{"award-number":["2025ZD0544400"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016834","name":"Chongqing Municipal Health Commission","doi-asserted-by":"publisher","award":["HBRC202408"],"award-info":[{"award-number":["HBRC202408"]}],"id":[{"id":"10.13039\/100016834","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.canlet.2026.218824","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T10:26:38Z","timestamp":1788949598000},"page":"218824","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target"],"prefix":"10.1016","volume":"660","author":[{"given":"Xiang","family":"Fang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiman","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengru","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3380-4545","authenticated-orcid":false,"given":"Yu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218824_bib1","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3390\/ncrna10010014","article-title":"MicroRNA-204 regulates angiogenesis and vasculogenic mimicry in CD44+\/CD24- breast cancer stem-like cells","volume":"10","author":"Resendiz-Hern\u00e1ndez","year":"2024","journal-title":"Non-coding RNA"},{"key":"10.1016\/j.canlet.2026.218824_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s40164-024-00519-1","article-title":"Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells","volume":"13","author":"Shi","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib3","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s10456-024-09913-z","article-title":"Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism","volume":"27","author":"Yang","year":"2024","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218824_bib4","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.169830","article-title":"CD93 maintains endothelial barrier function and limits metastatic dissemination","volume":"9","author":"Vemuri","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218824_bib5","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.devcel.2023.02.017","article-title":"A Lamb1Dendra2 mouse model identifies basement-membrane-producing origins and dynamics in PyMT breast tumors","volume":"58","author":"Morgner","year":"2023","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1171794","article-title":"Regulation of tumor angiogenesis by the crosstalk between innate immunity and endothelial cells","volume":"13","author":"Ebeling","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib8","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abm6388","article-title":"Tumors resurrect an embryonic vascular program to escape immunity","volume":"7","author":"Huijbers","year":"2022","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib9","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.molmed.2023.11.002","article-title":"Reprogramming endothelial cells to empower cancer immunotherapy","volume":"30","author":"Cleveland","year":"2024","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib10","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12935-023-03044-z","article-title":"Angiogenesis modulated by CD93 and its natural ligands IGFBP7 and MMRN2: a new target to facilitate solid tumor therapy by vasculature normalization","volume":"23","author":"Li","year":"2023","journal-title":"Cancer Cell Int."},{"key":"10.1016\/j.canlet.2026.218824_bib11","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010153","article-title":"Effector T cells under hypoxia have an altered transcriptome similar to tumor-stressed T cells found in non-responsive melanoma patients","volume":"13","author":"Nagy","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1038\/s41568-024-00736-0","article-title":"Targeting the tumour vasculature: from vessel destruction to promotion","volume":"24","author":"Guelfi","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s41571-024-00886-y","article-title":"Antiangiogenic\u2013immune-checkpoint inhibitor combinations: lessons from phase III clinical trials","volume":"21","author":"Kuo","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib14","doi-asserted-by":"crossref","DOI":"10.1002\/iid3.70408","article-title":"Vascular endothelial growth factor\/angiopoietin-2 bispecific antibody-induced vascular normalization: from basic mechanisms to therapeutic applications in breast cancer","volume":"14","author":"Li","year":"2026","journal-title":"Immun. Inflamm. Dis."},{"key":"10.1016\/j.canlet.2026.218824_bib15","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10555-026-10345-y","article-title":"Mechanobiology of solid tumor vasculature: implications for tumor progression","volume":"45","author":"Kondapaneni","year":"2026","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.canlet.2026.218824_bib16","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1038\/s43018-024-00780-7","article-title":"Milestones in tumor vascularization and its therapeutic targeting","volume":"5","author":"De Palma","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262211128","article-title":"Research progress regarding the use of single-cell sequencing technology in analyzing tumor endothelial cell pathophysiology","volume":"26","author":"Zhao","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41568-023-00591-5","article-title":"Understanding tumour endothelial cell heterogeneity and function from single-cell omics","volume":"23","author":"Zeng","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib19","doi-asserted-by":"crossref","first-page":"9853","DOI":"10.3390\/ijms25189853","article-title":"Towards targeting endothelial Rap1B to overcome vascular immunosuppression in cancer","volume":"25","author":"Ghadrdoost Nakhchi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib20","article-title":"Endothelial cell in tumor angiogenesis: origins, mechanisms, and therapeutic implication","volume":"12","author":"Han","year":"2025","journal-title":"Genes Dis."},{"key":"10.1016\/j.canlet.2026.218824_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.121438","article-title":"DLL4-Notch signalling in acute-on-chronic liver failure: state of the art and perspectives","volume":"317","author":"Zhou","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib22","doi-asserted-by":"crossref","first-page":"6415","DOI":"10.3390\/ijms25126415","article-title":"Molecular mechanisms regulating vascular endothelial permeability","volume":"25","author":"Wakasugi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib23","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ccell.2016.10.018","article-title":"Normalization of tumor vessels by Tie2 activation and Ang2 inhibition enhances drug delivery and produces a favorable tumor microenvironment","volume":"30","author":"Park","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib24","article-title":"VEGFR2 pY949 signalling regulates adherens junction integrity and metastatic spread","volume":"7","author":"Li","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40364-025-00883-y","article-title":"Tumor-associated endothelial cells in tumor immune escape and immunotherapy: multifaceted roles and treatment approaches","volume":"14","author":"Zheng","year":"2025","journal-title":"Biomark. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib26","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.cell.2020.08.040","article-title":"Onco-fetal reprogramming of endothelial cells drives immunosuppressive macrophages in hepatocellular carcinoma","volume":"183","author":"Sharma","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib27","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1016\/j.immuni.2025.07.008","article-title":"Mutations in MLL3 promote breast cancer progression via HIF1\u03b1-dependent intratumoral recruitment and differentiation of regulatory T cells","volume":"58","author":"Boutet","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218824_bib28","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1633845","article-title":"Hypoxia and activation of hypoxia inducible factor alpha as influencers of inflammatory helper T cells in autoimmune disease \u2013 a link between cancer and autoimmunity","volume":"16","author":"Almanzar","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib29","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41568-024-00761-z","article-title":"Convergent inducers and effectors of T cell paralysis in the tumour microenvironment","volume":"25","author":"Hanahan","year":"2025","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib30","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/s41419-025-07444-z","article-title":"Tumor vascular endothelial cells promote immune escape by upregulating PD-L1 expression via crosstalk between NF-\u03baB and STAT3 signaling pathways in nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.canlet.2026.218824_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2025.123297","article-title":"Selective vascular disrupting therapy by lipid nanoparticle-mediated fas ligand silencing and stimulation of STING","volume":"321","author":"Endo","year":"2025","journal-title":"Biomaterials"},{"key":"10.1016\/j.canlet.2026.218824_bib32","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1185985","article-title":"Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma","volume":"14","author":"Liang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib33","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1080\/07853890.2023.2180155","article-title":"Endothelial-to-mesenchymal transition in tumour progression and its potential roles in tumour therapy","volume":"55","author":"Yin","year":"2023","journal-title":"Ann. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib34","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1172\/JCI84876","article-title":"c-Met\u2013mediated endothelial plasticity drives aberrant vascularization and chemoresistance in glioblastoma","volume":"126","author":"Huang","year":"2016","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218824_bib35","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1038\/s41467-018-05982-z","article-title":"PDGF-Mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma","volume":"9","author":"Liu","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.jhep.2024.09.044","article-title":"CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma","volume":"82","author":"Lu","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218824_bib37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1152\/physrev.00037.2018","article-title":"Passing the vascular barrier: endothelial signaling processes controlling extravasation","volume":"99","author":"Wettschureck","year":"2019","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.canlet.2026.218824_bib38","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ccell.2023.02.019","article-title":"Transcriptome analysis reveals tumor microenvironment changes in glioblastoma","volume":"41","author":"Hoogstrate","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202405130","article-title":"Pericytes modulate third-generation tyrosine kinase inhibitor sensitivity in EGFR-Mutated lung cancer cells through IL32-\u03b25-integrin paracrine signaling","volume":"11","author":"Huang","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI179860","article-title":"Pericyte phenotype switching alleviates immunosuppression and sensitizes vascularized tumors to immunotherapy in preclinical models","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218824_bib41","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.trecan.2025.06.005","article-title":"Pericyte phenotype switching in cancer","volume":"11","author":"He","year":"2025","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib42","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nature06868","article-title":"Vascular normalization in Rgs5-deficient tumours promotes immune destruction","volume":"453","author":"Hamzah","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218824_bib43","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-024-07698-1","article-title":"Tumour vasculature at single-cell resolution","volume":"632","author":"Pan","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2026.218824_bib44","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s44318-024-00078-5","article-title":"Pericyte signaling via soluble guanylate cyclase shapes the vascular niche and microenvironment of tumors","volume":"43","author":"Zhu","year":"2024","journal-title":"EMBO J."},{"key":"10.1016\/j.canlet.2026.218824_bib45","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1161\/ATVBAHA.123.319119","article-title":"Extracellular matrix stiffness regulates microvascular stability by controlling endothelial paracrine signaling to determine pericyte fate","volume":"43","author":"Yu","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib46","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1038\/s41467-020-18794-x","article-title":"Concepts of extracellular matrix remodelling in tumour progression and metastasis","volume":"11","author":"Winkler","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib47","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.ajpath.2025.09.008","article-title":"Inhibiting the secreted RGDKGE collagen peptide selectively controls CD8+ T-cell migration on denatured collagen-IV and enhances their accumulation in tumors","volume":"196","author":"Han","year":"2026","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218824_bib48","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/j.apsb.2020.09.014","article-title":"Manipulation of immune\u2013vascular crosstalk: new strategies towards cancer treatment","volume":"10","author":"Zhao","year":"2020","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218824_bib49","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s10585-026-10405-1","article-title":"Matrix and stromal cues cooperatively regulate dormancy-like states of prostate cancer in a dual-niche metastatic model","volume":"43","author":"Han","year":"2026","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.canlet.2026.218824_bib50","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-025-66985-1","article-title":"Pericytes orchestrate a tumor-restraining microenvironment in glioblastoma","volume":"16","author":"Braun","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib51","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.immuni.2025.02.022","article-title":"Single-cell atlas of endothelial and mural cells across primary and metastatic brain tumors","volume":"58","author":"Bejarano","year":"2025","journal-title":"Immunity"},{"key":"10.1016\/j.canlet.2026.218824_bib52","doi-asserted-by":"crossref","first-page":"2177","DOI":"10.1158\/1538-7445.AM2025-2177","article-title":"Spatial transcriptomic and functional analysis of HLA\/PD-1\/CTLA4 multi-gene edited CD19 CAR-iNK cells targeting pericytes in the glioblastoma tumor microenvironment to inhibit tumor migration and growth","volume":"85","author":"Kang","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib53","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.stem.2017.10.002","article-title":"Targeting glioma stem cell-derived pericytes disrupts the blood-tumor barrier and improves chemotherapeutic efficacy","volume":"21","author":"Zhou","year":"2017","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib54","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1002\/cam4.105","article-title":"Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?","volume":"2","author":"Donnem","year":"2013","journal-title":"Cancer Med."},{"key":"10.1016\/j.canlet.2026.218824_bib55","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.3390\/cells13221835","article-title":"Modeling lymphoma angiogenesis, lymphangiogenesis, and vessel co-option, and the effects of inhibition of lymphoma\u2013vessel interactions with an \u03b1CD20-EndoP125A antibody fusion protein","volume":"13","author":"Elledge","year":"2024","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218824_bib56","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1038\/s41556-024-01532-6","article-title":"Differential stiffness between brain vasculature and parenchyma promotes metastatic infiltration through vessel co-option","volume":"26","author":"Uroz","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib57","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/0008-5472.CAN-10-3396","article-title":"Angiocrine factors modulate tumor proliferation and motility through EphA2 repression of Slit2 tumor suppressor function in endothelium","volume":"71","author":"Brantley-Sieders","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib58","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/ncb2767","article-title":"The perivascular niche regulates breast tumour dormancy","volume":"15","author":"Ghajar","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib59","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.7150\/thno.37851","article-title":"Specific targeting of PDGFR\u03b2 in the Stroma inhibits growth and angiogenesis in tumors with high PDGF-BB expression","volume":"10","author":"Tsioumpekou","year":"2020","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218824_bib60","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-13-0011","article-title":"\u03b21 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma","volume":"73","author":"Carbonell","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib61","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/path.4304","article-title":"Angiopoietin-2 mediates blood\u2013brain barrier impairment and colonization of triple-negative breast cancer cells in brain","volume":"232","author":"Avraham","year":"2014","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218824_bib62","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.107805","article-title":"Vasculogenic mimicry, a complex and devious process favoring tumorigenesis \u2013 interest in making it a therapeutic target","volume":"223","author":"Treps","year":"2021","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.canlet.2026.218824_bib63","article-title":"During the formation of vasculogenic mimicry by melanoma cells, the silencing of two sets of developmental genes is coupled either with an increase or a decrease in contacts with the nucleoli","volume":"26","author":"Tchurikov","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252111789","article-title":"Ruta graveolens, but not rutin, inhibits survival, migration, invasion, and vasculogenic mimicry of glioblastoma cells","volume":"25","author":"Camerino","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib65","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/pros.10048","article-title":"Prostatic tumor cell plasticity involves cooperative interactions of distinct phenotypic subpopulations: role in vasculogenic mimicry","volume":"50","author":"Sharma","year":"2002","journal-title":"Prostate"},{"key":"10.1016\/j.canlet.2026.218824_bib66","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/path.6043","article-title":"PARP inhibition promotes endothelial-like traits in melanoma cells and modulates pericyte coverage dynamics during vasculogenic mimicry","volume":"259","author":"Fern\u00e1ndez-Cort\u00e9s","year":"2023","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218824_bib67","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1186\/s12964-025-02428-0","article-title":"Extracellular matrix protein signaling promotes multi-step cancer vasculogenic mimicry formation","volume":"23","author":"Mingo","year":"2025","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.canlet.2026.218824_bib68","doi-asserted-by":"crossref","first-page":"8729","DOI":"10.1007\/s00432-023-04790-3","article-title":"Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer","volume":"149","author":"Fan","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib69","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1136\/gutjnl-2024-333638","article-title":"Endothelial-like cancer-associated fibroblasts facilitate pancreatic cancer metastasis via vasculogenic mimicry and paracrine signalling","volume":"74","author":"Sun","year":"2025","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2026.218824_bib70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/path.5152","article-title":"Targeting PDGF-Mediated recruitment of pericytes blocks vascular mimicry and tumor growth","volume":"246","author":"Thijssen","year":"2018","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218824_bib71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1186\/s12967-025-07354-w","article-title":"Vessels encapsulating tumor clusters in hepatocellular carcinoma: a distinct metastatic pathway with diagnostic and therapeutic significance","volume":"24","author":"Zhu","year":"2026","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib72","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.21037\/tcr.2020.04.11","article-title":"Clinicopathological and prognostic implications of vessels encapsulate tumor clusters with PD-L1 in intrahepatic cholangiocarcinoma patients","volume":"9","author":"Tao","year":"2020","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib73","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16554","article-title":"Prognostic and predictive value of vessels encapsulating tumor clusters (VETC) in renal cell carcinoma (RCC)","volume":"39","author":"Renne","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib74","first-page":"654","article-title":"Angiopoietin-2 regulates vessels encapsulated by tumor clusters positive hepatocellular carcinoma nest-type metastasis via integrin \u03b15\u03b21","volume":"101","author":"Dong","year":"2021","journal-title":"Zhonghua Yixue Zazhi"},{"key":"10.1016\/j.canlet.2026.218824_bib75","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1007\/s13402-025-01073-6","article-title":"Pericytes in hematogenous metastasis: mechanistic insights and therapeutic approaches","volume":"48","author":"Xu","year":"2025","journal-title":"Cell. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib76","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/labinvest.3780270","article-title":"Human hepatocellular carcinoma (HCC) cells require both \u03b13\u03b21 integrin and matrix metalloproteinases activity for migration and invasion","volume":"81","author":"Giannelli","year":"2001","journal-title":"Lab. Invest."},{"key":"10.1016\/j.canlet.2026.218824_bib77","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/hep.30366","article-title":"Vessels that encapsulate tumor clusters (VETC) pattern is a predictor of sorafenib benefit in patients with hepatocellular carcinoma","volume":"70","author":"Fang","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218824_bib78","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1007\/s12072-021-10183-w","article-title":"A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion","volume":"15","author":"Lu","year":"2021","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.canlet.2026.218824_bib79","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1002\/path.4804","article-title":"MicroRNAs miR-125b and miR-100 suppress metastasis of hepatocellular carcinoma by disrupting the formation of vessels that encapsulate tumour clusters","volume":"240","author":"Zhou","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.canlet.2026.218824_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.726492","article-title":"Multi-parameter quantitative imaging of tumor microenvironments reveals perivascular immune niches associated with anti-tumor immunity","volume":"12","author":"Stoltzfus","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib81","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib82","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib83","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143762","article-title":"The changing role of natural killer cells in cancer metastasis","volume":"132","author":"Chan","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.canlet.2026.218824_bib84","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70231","article-title":"Myeloid-derived suppressor cells in cancer: mechanistic insights and targeted therapeutic innovations","volume":"6","author":"Hu","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.canlet.2026.218824_bib85","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/ijms27083645","article-title":"Integrative in silico and FFPE tissue analyses elucidate upregulated genes in colorectal cancer enriched for Tie2-expressing macrophages\/monocytes","volume":"27","author":"Ali","year":"2026","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib86","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.3390\/cancers17071232","article-title":"Neutrophils and neutrophil-based drug delivery systems in anti-cancer therapy","volume":"17","author":"Wahnou","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218824_bib87","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1084\/jem.20091739","article-title":"Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels","volume":"206","author":"Pflicke","year":"2009","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib88","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1126\/science.1228456","article-title":"Interstitial dendritic cell guidance by haptotactic chemokine gradients","volume":"339","author":"Weber","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.canlet.2026.218824_bib89","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s00018-023-04788-7","article-title":"CCL21-CCR7 signaling promotes microglia\/macrophage recruitment and chemotherapy resistance in glioblastoma","volume":"80","author":"Geraldo","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib90","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4712","article-title":"Tumor lymphangiogenesis promotes T cell infiltration and potentiates immunotherapy in melanoma","volume":"9","author":"Fankhauser","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib91","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1084\/jem.20180654","article-title":"IFN\u03b3-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin","volume":"215","author":"Lane","year":"2018","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib92","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ccell.2023.04.010","article-title":"Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma","volume":"41","author":"Ramachandran","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib93","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.ccell.2022.11.002","article-title":"Cancer immunotherapies transition endothelial cells into HEVs that generate TCF1+ T lymphocyte niches through a feed-forward loop","volume":"40","author":"Hua","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib94","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3389\/fimmu.2016.00407","article-title":"Tertiary lymphoid structures in cancers: prognostic value, regulation, and manipulation for therapeutic intervention","volume":"7","author":"Saut\u00e8s-Fridman","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib95","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.trecan.2024.08.002","article-title":"Immunomodulation by endothelial cells: prospects for cancer therapy","volume":"10","author":"Alnaqbi","year":"2024","journal-title":"Trends Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib96","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ccell.2023.02.016","article-title":"The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth","volume":"41","author":"De Visser","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib97","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay0555","article-title":"VEGF-A drives TOX-Dependent T cell exhaustion in anti\u2013PD-1\u2013resistant microsatellite stable colorectal cancers","volume":"4","author":"Kim","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib98","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/s43018-023-00672-2","article-title":"Presence of onco-fetal neighborhoods in hepatocellular carcinoma is associated with relapse and response to immunotherapy","volume":"5","author":"Li","year":"2024","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib99","doi-asserted-by":"crossref","first-page":"5511","DOI":"10.1038\/s41467-022-33052-y","article-title":"Single cell atlas identifies lipid-processing and immunomodulatory endothelial cells in healthy and malignant breast","volume":"13","author":"Geldhof","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41577-022-00694-4","article-title":"Immunomodulation by endothelial cells \u2014 partnering up with the immune system?","volume":"22","author":"Amersfoort","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib101","article-title":"The emerging roles of pericytes in modulating tumor microenvironment","volume":"9","author":"Sun","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib102","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.cjtee.2020.02.006","article-title":"Research advances in pericyte function and their roles in diseases","volume":"23","author":"Zhang","year":"2020","journal-title":"Chin. J. Traumatol. (Engl. Ed.)"},{"key":"10.1016\/j.canlet.2026.218824_bib103","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3389\/fimmu.2016.00480","article-title":"Immune regulation by pericytes: modulating innate and adaptive immunity","volume":"7","author":"Navarro","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib104","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib105","article-title":"The PDGF-BB-SOX7 axis-modulated IL-33 in pericytes and stromal cells promotes metastasis through tumour-associated macrophages","volume":"7","author":"Yang","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib106","doi-asserted-by":"crossref","first-page":"20655","DOI":"10.1073\/pnas.1903542116","article-title":"Glioblastoma ablates pericytes antitumor immune function through aberrant up-regulation of chaperone-mediated autophagy","volume":"116","author":"Valdor","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218824_bib107","doi-asserted-by":"crossref","first-page":"971","DOI":"10.4049\/jimmunol.1300280","article-title":"Tumor-derived vascular pericytes anergize Th cells","volume":"191","author":"Bose","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib108","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jneuroim.2013.09.011","article-title":"Immature mesenchymal stem cell-like pericytes as mediators of immunosuppression in human malignant glioma","volume":"265","author":"Ochs","year":"2013","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.canlet.2026.218824_bib109","doi-asserted-by":"crossref","first-page":"2300","DOI":"10.1002\/ijc.25236","article-title":"Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-Cell infiltration and positioning of malignant B cells","volume":"127","author":"Venetz","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib110","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.607891","article-title":"MAPKAP kinase-2 drives expression of angiogenic factors by tumor-associated macrophages in a model of inflammation-induced Colon cancer","volume":"11","author":"Suarez-Lopez","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib111","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28332","article-title":"Macrophage diversity in human cancers: new insight provided by single-cell resolution and spatial context","volume":"10","author":"Rakina","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.canlet.2026.218824_bib112","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.ccell.2024.03.013","article-title":"Identification of hypoxic macrophages in glioblastoma with therapeutic potential for vasculature normalization","volume":"42","author":"Wang","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib113","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s12672-023-00793-1","article-title":"Regulation of T cells by myeloid-derived suppressor cells: emerging immunosuppressor in lung cancer","volume":"14","author":"He","year":"2023","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib114","article-title":"Bv8 mediates myeloid cell migration and enhances malignancy of colorectal cancer","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib115","article-title":"CXCL9\/10-engineered dendritic cells promote T cell activation and enhance immune checkpoint blockade for lung cancer","volume":"5","author":"Lim","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1487610","article-title":"Leveraging the synergy between anti-angiogenic therapy and immune checkpoint inhibitors to treat digestive system cancers","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib117","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54874-y","article-title":"Regulatory T cells crosstalk with tumor cells and endothelium through lymphotoxin signaling","volume":"15","author":"Piao","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib118","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10456-013-9397-y","article-title":"Interferon-\u03b3 produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells","volume":"17","author":"Lu","year":"2014","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218824_bib119","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2017.145","article-title":"Improving immune\u2013vascular crosstalk for cancer immunotherapy","volume":"18","author":"Huang","year":"2018","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib120","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/s12276-020-00500-y","article-title":"Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity","volume":"52","author":"Lee","year":"2020","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib121","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/ni.3836","article-title":"De novo induction of intratumoral lymphoid structures and vessel normalization enhances immunotherapy in resistant tumors","volume":"18","author":"Johansson-Percival","year":"2017","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib122","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404778121","article-title":"Metformin synergizes with PD-1 blockade to promote normalization of tumor vessels via CD8+ T cells and IFN\u03b3","volume":"121","author":"Tokumasu","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218824_bib123","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.4049\/jimmunol.2300326","article-title":"Dose-specific intratumoral GM-CSF modulates breast tumor oxygenation and antitumor immunity","volume":"211","author":"Mihalik","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib124","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1038\/onc.2013.160","article-title":"Tumor-derived mural-like cells coordinate with endothelial cells: role of YKL-40 in mural cell-mediated angiogenesis","volume":"33","author":"Francescone","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2026.218824_bib125","doi-asserted-by":"crossref","first-page":"32301","DOI":"10.1021\/acsami.0c06949","article-title":"Fever-inducible lipid nanocomposite for boosting cancer therapy through synergistic engineering of a tumor microenvironment","volume":"12","author":"Qu","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.canlet.2026.218824_bib126","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13578-024-01201-z","article-title":"Macrophage heterogeneity and its interactions with stromal cells in tumour microenvironment","volume":"14","author":"Cao","year":"2024","journal-title":"Cell Biosci."},{"key":"10.1016\/j.canlet.2026.218824_bib127","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001906","article-title":"STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment","volume":"9","author":"Chelvanambi","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/nrc1094","article-title":"Basement membranes: structure, assembly and role in tumour angiogenesis","volume":"3","author":"Kalluri","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib129","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1097\/01.sla.0000231723.81218.72","article-title":"Tumor necrosis factor-alpha damages tumor blood vessel integrity by targeting VE-cadherin","volume":"244","author":"Menon","year":"2006","journal-title":"Ann. Surg."},{"key":"10.1016\/j.canlet.2026.218824_bib130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ccr.2009.06.017","article-title":"Polarization of tumor-associated neutrophil phenotype by TGF-\u03b2: \u201cN1\u201d versus \u201cN2\u201d TAN","volume":"16","author":"Fridlender","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib131","doi-asserted-by":"crossref","first-page":"6742","DOI":"10.1073\/pnas.0902280106","article-title":"G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models","volume":"106","author":"Shojaei","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.canlet.2026.218824_bib132","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2022.1081376","article-title":"TGF-\u03b2 signaling in lymphatic vascular vessel formation and maintenance","volume":"13","author":"Itoh","year":"2022","journal-title":"Front. Physiol."},{"key":"10.1016\/j.canlet.2026.218824_bib133","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/s41580-023-00631-w","article-title":"Biology and therapeutic targeting of vascular endothelial growth factor A","volume":"24","author":"P\u00e9rez-Guti\u00e9rrez","year":"2023","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib134","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1186\/s12885-022-09630-0","article-title":"Overexpression of angiogenic factors and matrix metalloproteinases in the saliva of oral squamous cell carcinoma patients: potential non-invasive diagnostic and therapeutic biomarkers","volume":"22","author":"Cai","year":"2022","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib135","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41467-017-01599-w","article-title":"Loss of HIF-1\u03b1 in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis","volume":"8","author":"Krzywinska","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib136","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.924775","article-title":"NK cells under hypoxia: the two faces of vascularization in tumor and pregnancy","volume":"13","author":"Garc\u00e9s-L\u00e1zaro","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib137","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.90905","article-title":"Sustained inflammation after pericyte depletion induces irreversible blood-retina barrier breakdown","volume":"2","author":"Ogura","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.canlet.2026.218824_bib138","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.canlet.2026.218824_bib139","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Sherwood","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib140","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s12672-024-01049-2","article-title":"Advances in the molecular regulation mechanism of tumor dormancy and its therapeutic strategy","volume":"15","author":"Wang","year":"2024","journal-title":"Discov. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib141","article-title":"Endostatin-based anti-angiogenic therapy and immune modulation: mechanisms and synergistic potential in cancer treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib142","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/s41573-023-00671-z","article-title":"Targeting angiogenesis in oncology, ophthalmology and beyond","volume":"22","author":"Cao","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218824_bib143","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41392-020-00264-x","article-title":"Targeted therapy for hepatocellular carcinoma","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218824_bib144","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1111\/hepr.14045","article-title":"Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: involvement of transforming growth factor-\u03b2 signaling in their molecular effects","volume":"54","author":"Wang","year":"2024","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib145","doi-asserted-by":"crossref","first-page":"489","DOI":"10.32604\/or.2023.046676","article-title":"Gastric cancer secreted miR-214-3p inhibits the anti-angiogenesis effect of apatinib by suppressing ferroptosis in vascular endothelial cells","volume":"32","author":"Wang","year":"2024","journal-title":"Oncol. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib146","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/s41598-023-50369-w","article-title":"Apatinib weakens proliferation, migration, invasion, and angiogenesis of thyroid cancer cells through downregulating pyruvate kinase M2","volume":"14","author":"Yang","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218824_bib147","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2017.9","article-title":"Renal cell carcinoma","volume":"3","author":"Hsieh","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.canlet.2026.218824_bib221","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S0140-6736(23)00961-3","article-title":"Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218824_bib222","doi-asserted-by":"crossref","first-page":"5610","DOI":"10.1182\/blood-2007-02-075945","article-title":"Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses","volume":"111","author":"Hipp","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2026.218824_bib223","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001435","article-title":"Regorafenib combined with PD1 blockade increases CD8 T-cell infiltration by inducing CXCL10 expression in hepatocellular carcinoma","volume":"8","author":"Shigeta","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib224","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1186\/s13046-021-02043-0","article-title":"Regorafenib enhances anti-PD1 immunotherapy efficacy in murine colorectal cancers and their combination prevents tumor regrowth","volume":"40","author":"Doleschel","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib225","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001657","article-title":"Regorafenib enhances antitumor immunity via inhibition of p38 kinase\/Creb1\/Klf4 axis in tumor-associated macrophages","volume":"9","author":"Ou","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib226","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1158\/0008-5472.CAN-24-2697","article-title":"Combining apatinib and oxaliplatin remodels the immunosuppressive tumor microenvironment and sensitizes desert-type gastric cancer to immunotherapy","volume":"85","author":"Lin","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib227","article-title":"Anlotinib combined with anti-PD1 potentiates anti-tumor immunity via immunogenic cell death and macrophage reprogramming","volume":"6","author":"Zou","year":"2023","journal-title":"Adv. Ther."},{"key":"10.1016\/j.canlet.2026.218824_bib228","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1158\/1078-0432.CCR-21-2241","article-title":"Anlotinib induces a T cell-inflamed tumor microenvironment by facilitating vessel normalization and enhances the efficacy of PD-1 checkpoint blockade in neuroblastoma","volume":"28","author":"Su","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib229","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1738","article-title":"Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8+ T-cell infiltration in hepatocellular carcinoma","volume":"14","author":"Song","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib230","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109470","article-title":"Myeloid-derived suppressor cells (MDSCs) depletion by cabozantinib improves the efficacy of anti-HER2 antibody-based immunotherapy in a 4T1-HER2 murine breast cancer model","volume":"113","author":"Khaki Bakhtiarvand","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218824_bib231","article-title":"The beneficial role of sunitinib in tumor immune surveillance by regulating tumor PD-L1","volume":"8","author":"Li","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib232","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.biopha.2014.07.002","article-title":"Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid-derived suppressor cell accumulation","volume":"68","author":"Yuan","year":"2014","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218824_bib233","doi-asserted-by":"crossref","first-page":"36245","DOI":"10.18632\/oncotarget.5768","article-title":"Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells","volume":"6","author":"Morelli","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2026.218824_bib234","doi-asserted-by":"crossref","first-page":"747","DOI":"10.7150\/thno.65828","article-title":"Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells","volume":"12","author":"Tu","year":"2022","journal-title":"Theranostics"},{"key":"10.1016\/j.canlet.2026.218824_bib235","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.canlet.2026.218824_bib236","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(18)30207-1","article-title":"Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial","volume":"391","author":"Kudo","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218824_bib237","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100217","article-title":"Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST)","volume":"6","author":"Eriksson","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218824_bib238","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1696460","article-title":"Pazopanib-associated remodeling of platelet-immune cell crosstalk and immune suppressive platelet-derived extracellular vesicles in metastatic RCC","volume":"16","author":"Lupoli","year":"2026","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib239","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/ijms21010010","article-title":"Multikinase inhibitor treatment in thyroid cancer","volume":"21","author":"Ancker","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib240","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.pdpdt.2019.06.008","article-title":"Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment","volume":"27","author":"Chua","year":"2019","journal-title":"Photodiagnosis Photodyn. Ther."},{"key":"10.1016\/j.canlet.2026.218824_bib241","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.2018.7855","article-title":"Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial","volume":"319","author":"Li","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.canlet.2026.218824_bib242","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1699980","article-title":"Fruquintinib saddles tumor immune tolerance by curbing pro-tumoral immature myeloid cell populations","volume":"16","author":"Su\u00e1rez","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib243","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/17512433.2020.1702025","article-title":"Erdafitinib for the treatment of metastatic bladder cancer","volume":"13","author":"Montazeri","year":"2020","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218824_bib244","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ejca.2020.12.008","article-title":"Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: long-term efficacy and safety data from the NAVIGATOR phase I trial","volume":"145","author":"Jones","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib245","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.jare.2024.08.023","article-title":"Dialog between mantle cell lymphoma cells and lymphoma-associated macrophages underlies ibrutinib resistance","volume":"73","author":"Sun","year":"2025","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib246","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jconrel.2024.03.047","article-title":"Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood\u2013tumor barrier for boosted brain tumor therapy","volume":"369","author":"Mu","year":"2024","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.canlet.2026.218824_bib247","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib248","article-title":"Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies","volume":"13","author":"Zhang","year":"2025","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.canlet.2026.218824_bib249","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.812916","article-title":"Interactions between anti-angiogenic therapy and immunotherapy in glioblastoma","volume":"11","author":"Jain","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib250","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/PPO.0000000000000327","article-title":"Combinations of Bevacizumab with cancer immunotherapy","volume":"24","author":"Chen","year":"2018","journal-title":"Cancer J."},{"key":"10.1016\/j.canlet.2026.218824_bib251","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/S1470-2045(18)30937-9","article-title":"Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased \u03b1-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Zhu","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib252","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-018-0403-1","article-title":"Targeting VEGFR2 with Ramucirumab strongly impacts effector\/activated regulatory T cells and CD8+ T cells in the tumor microenvironment","volume":"6","author":"Tada","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib253","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib254","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2017.12.026","article-title":"Olaratumab in soft tissue sarcoma \u2013 current status and future perspectives","volume":"92","author":"Antoniou","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib255","doi-asserted-by":"crossref","first-page":"8604","DOI":"10.1200\/JCO.2024.42.16_suppl.8604","article-title":"Efficacy and safety of MCLA-129, an EGFR\/c-MET bispecific antibody, in advanced non-small cell lung cancer (NSCLC)","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib256","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1158\/1535-7163.MCT-22-0596","article-title":"Preclinical profile of BYON3521 predicts an effective and safe MET antibody-drug conjugate","volume":"22","author":"Groothuis","year":"2023","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.canlet.2026.218824_bib257","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1038\/s41467-025-60074-z","article-title":"Glioma-neuronal circuit remodeling induces regional immunosuppression","volume":"16","author":"Nejo","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib258","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/s41590-025-02321-5","article-title":"Thrombospondin-1-CD47 signaling contributes to the development of T cell exhaustion in cancer","volume":"26","author":"Weng","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib259","doi-asserted-by":"crossref","first-page":"510","DOI":"10.3390\/cancers16030510","article-title":"The various roles of PEDF in cancer","volume":"16","author":"Elmi","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218824_bib260","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-015-0278-7","article-title":"Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review","volume":"35","author":"Belkacemi","year":"2016","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib261","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jhep.2023.08.007","article-title":"Combined inhibition of surface CD51 and \u03b3-secretase-mediated CD51 cleavage improves therapeutic efficacy in experimental metastatic hepatocellular carcinoma","volume":"79","author":"Cai","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218824_bib262","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1158\/0008-5472.CAN-15-2663","article-title":"Antagonizing integrin beta3 increases immune suppression in cancer","volume":"76","author":"Su","year":"2016","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib263","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2024.111747","article-title":"PI3K\u03b1 inhibitor GNE-493 triggers antitumor immunity in murine lung cancer by inducing immunogenic cell death and activating T cells","volume":"130","author":"Xue","year":"2024","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.canlet.2026.218824_bib264","article-title":"Reduced energy metabolism impairs T cell-dependent B cell responses in patients with advanced HBV-related cirrhosis","volume":"12","author":"Huang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib265","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1007\/s00120-011-2553-3","article-title":"Sequenztherapie beim metastasierten Nierenzellkarzinom in Deutschland 2010","volume":"50","author":"Siebels","year":"2011","journal-title":"Urologe"},{"key":"10.1016\/j.canlet.2026.218824_bib266","doi-asserted-by":"crossref","first-page":"11240","DOI":"10.1080\/21655979.2022.2064205","volume":"13","author":"Song","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.canlet.2026.218824_bib267","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jaad.2025.03.023","article-title":"Efficacy and safety of high- vs low-dose sirolimus in patients with kaposiform hemangioendothelioma: a randomized clinical trial","volume":"93","author":"Zhou","year":"2025","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.canlet.2026.218824_bib268","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1509891","article-title":"Pemigatinib combined with immunotherapy and stereotactic body radiation therapy for FGFR2 fusion-positive advanced intrahepatic cholangiocarcinoma with brain metastasis: a case report","volume":"15","author":"Guo","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218824_bib269","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103625","article-title":"Open-label, dose-escalation FIGHT-101 study of pemigatinib combined with targeted therapy, chemotherapy, or immunotherapy in patients with advanced malignancies","volume":"9","author":"Saleh","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218824_bib270","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1254\/fpj.24045","article-title":"Pharmacological characteristics and clinical effectiveness of futibatinib (Lytgobi\u00ae tablets), a covalently-binding, irreversible FGFR1-4 inhibitor","volume":"159","author":"Takagaki","year":"2024","journal-title":"Nihon Yakurigaku Zasshi"},{"key":"10.1016\/j.canlet.2026.218824_bib271","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11523-024-01119-z","article-title":"FGFR-altered urothelial carcinoma: resistance mechanisms and therapeutic strategies","volume":"20","author":"Benjamin","year":"2025","journal-title":"Targeted Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib148","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.cell.2023.12.011","article-title":"Bispecific dendritic-T cell engager potentiates anti-tumor immunity","volume":"187","author":"Shapir Itai","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib149","doi-asserted-by":"crossref","first-page":"79","DOI":"10.24294\/ti.v5.i2.1.1376","article-title":"Combination of anti-angiogenic therapy apatinib and immune therapy potentiate tumor microenvironment","volume":"5","author":"Gao","year":"2021","journal-title":"Trends Immunother"},{"key":"10.1016\/j.canlet.2026.218824_bib150","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1158\/2326-6066.CIR-24-0876","article-title":"Secretion of a VEGF-Blocking scFv enhances CAR T-cell potency","volume":"13","author":"Supper","year":"2025","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib151","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib152","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s00262-016-1824-7","article-title":"Endostatin inhibits the growth and migration of 4T1 mouse breast cancer cells by skewing macrophage polarity toward the M1 phenotype","volume":"65","author":"Guo","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218824_bib153","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1265865","article-title":"Research advances in mechanism of antiangiogenic therapy combined with immune checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"14","author":"He","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.canlet.2026.218824_bib154","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib155","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/nrc3366","article-title":"Controlling escape from angiogenesis inhibitors","volume":"12","author":"Sennino","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib156","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm0901-987","article-title":"Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy","volume":"7","author":"Jain","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib157","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.canlet.2026.218824_bib158","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1760685","article-title":"Regulation of the tumor immune microenvironment and vascular normalization in TNBC murine models by a novel peptide","volume":"9","author":"Mirando","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218824_bib159","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202101093R","article-title":"NLGP regulates RGS5-TGF\u03b2 axis to promote pericyte-dependent vascular normalization during restricted tumor growth","volume":"36","author":"Dasgupta","year":"2022","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2026.218824_bib160","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202207650","article-title":"The combination of R848 with sorafenib enhances antitumor effects by reprogramming the tumor immune microenvironment and facilitating vascular normalization in hepatocellular carcinoma","volume":"10","author":"He","year":"2023","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib161","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s13045-020-00952-9","article-title":"Tie2-mediated vascular remodeling by ferritin-based protein C nanoparticles confers antitumor and anti-metastatic activities","volume":"13","author":"Choi","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib162","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.taap.2015.03.021","article-title":"Dopamine induces growth inhibition and vascular normalization through reprogramming M2-polarized macrophages in rat C6 glioma","volume":"286","author":"Qin","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.canlet.2026.218824_bib163","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S1470-2045(16)00078-4","article-title":"Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial","volume":"17","author":"Nywening","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib164","first-page":"869","article-title":"TNFSF15 facilitates the differentiation of CD11b+ myeloid cells into vascular pericytes in tumors","volume":"20","author":"Gu","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib165","doi-asserted-by":"crossref","first-page":"4265","DOI":"10.3390\/cancers14174265","article-title":"Nucleolin therapeutic targeting decreases pancreatic cancer immunosuppression","volume":"14","author":"Ponzo","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218824_bib166","doi-asserted-by":"crossref","first-page":"5365","DOI":"10.1096\/fj.201701103R","article-title":"Angiogenin and the MMP9-TIMP2 axis are up-regulated in proangiogenic, decidual NK-like cells from patients with colorectal cancer","volume":"32","author":"Bruno","year":"2018","journal-title":"FASEB J."},{"key":"10.1016\/j.canlet.2026.218824_bib167","doi-asserted-by":"crossref","first-page":"120","DOI":"10.34133\/bmr.0120","article-title":"A novel cell-penetrating peptide\u2013vascular endothelial growth factor small interfering ribonucleic acid complex that mediates the inhibition of angiogenesis by human umbilical vein endothelial cells and in an ex vivo mouse aorta ring model","volume":"29","author":"Kim","year":"2025","journal-title":"Biomater. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib168","doi-asserted-by":"crossref","first-page":"144","DOI":"10.34133\/bmr.0144","article-title":"Lipid nanoparticle delivery system for normalization of tumor microenvironment and tumor vascular structure","volume":"29","author":"Ha","year":"2025","journal-title":"Biomater. Res."},{"key":"10.1016\/j.canlet.2026.218824_bib169","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s43018-020-00147-8","article-title":"Targeting PAK4 to reprogram the vascular microenvironment and improve CAR-T immunotherapy for glioblastoma","volume":"2","author":"Ma","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib170","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1016\/j.scib.2023.06.031","article-title":"Inhibiting redox-mediated endothelial migration by gadofullerenes for inducing tumor vascular normalization and improving chemotherapy","volume":"68","author":"Sun","year":"2023","journal-title":"Sci. Bull."},{"key":"10.1016\/j.canlet.2026.218824_bib171","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/ATVBAHA.119.313536","article-title":"Proinflammatory mediators, IL (interleukin)-1\u03b2, TNF (tumor necrosis factor) \u03b1, and thrombin directly induce capillary tube regression","volume":"40","author":"Koller","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib172","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1038\/s41467-021-26259-y","article-title":"Hexokinase 2-driven glycolysis in pericytes activates their contractility leading to tumor blood vessel abnormalities","volume":"12","author":"Meng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.canlet.2026.218824_bib173","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/cells14080593","article-title":"LRG1 alters pericyte phenotype and compromises vascular maturation","volume":"14","author":"Hoeh","year":"2025","journal-title":"Cells"},{"key":"10.1016\/j.canlet.2026.218824_bib174","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","article-title":"Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy","volume":"30","author":"Cantelmo","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2045-824X-6-1","article-title":"Netrin-4 promotes mural cell adhesion and recruitment to endothelial cells","volume":"6","author":"Lejmi","year":"2014","journal-title":"Vasc. Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib176","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.tranon.2016.07.004","article-title":"Noninvasive assessment of losartan-induced increase in functional microvasculature and drug delivery in pancreatic ductal adenocarcinoma","volume":"9","author":"Kumar","year":"2016","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib177","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.20.00590","article-title":"Randomized phase III trial of pegvorhyaluronidase alfa with nab-paclitaxel plus gemcitabine for patients with hyaluronan-high metastatic pancreatic adenocarcinoma","volume":"38","author":"Van Cutsem","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib178","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1200\/JCO.2015.62.8719","article-title":"Randomized phase Ib\/II study of gemcitabine plus placebo or vismodegib, a hedgehog pathway inhibitor, in patients with metastatic pancreatic cancer","volume":"33","author":"Catenacci","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib179","doi-asserted-by":"crossref","first-page":"4140","DOI":"10.1039\/D2BM00600F","article-title":"Combination of tumor vessel normalization and immune checkpoint blockade for breast cancer treatment via multifunctional nanocomplexes","volume":"10","author":"Zeng","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib180","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.actbio.2026.01.050","article-title":"Elevated interstitial fluid pressure promotes spheroid growth and reduces CAR-T therapeutic efficacy in solid tumors","volume":"213","author":"Alam\u00e1n-D\u00edez","year":"2026","journal-title":"Acta Biomater."},{"key":"10.1016\/j.canlet.2026.218824_bib181","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.apsb.2022.02.014","article-title":"Targeting tumor endothelial hyperglycolysis enhances immunotherapy through remodeling tumor microenvironment","volume":"12","author":"Shan","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.canlet.2026.218824_bib182","doi-asserted-by":"crossref","first-page":"643","DOI":"10.3892\/mmr.2016.5314","article-title":"TNF-\u03b1 enhances vascular cell adhesion molecule-1 expression in human bone marrow mesenchymal stem cells via the NF-\u03baB, ERK and JNK signaling pathways","volume":"14","author":"Lu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.canlet.2026.218824_bib183","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1158\/0008-5472.CAN-22-2838","article-title":"Angiopoietin-2-dependent spatial vascular destabilization promotes T-cell exclusion and limits immunotherapy in melanoma","volume":"83","author":"Park","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib184","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S0959-8049(22)00831-0","article-title":"Taxanes act as vascular disrupting agents and increase rate of metastasis when combined with angiogenic therapy","volume":"174","author":"Henke","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.semcancer.2019.07.023","article-title":"Flavonoids nanoparticles in cancer: treatment, prevention and clinical prospects","volume":"69","author":"Khan","year":"2021","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib186","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/12469","article-title":"Anti-cancer activity of targeted pro-apoptotic peptides","volume":"5","author":"Ellerby","year":"1999","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib187","doi-asserted-by":"crossref","DOI":"10.1177\/1010428317691001","article-title":"Tumor rim cells: from resistance to vascular targeting agents to complete tumor ablation","volume":"39","author":"Seidi","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.canlet.2026.218824_bib188","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-64610-7","article-title":"Targeting vascular disrupting agent-treated tumor microenvironment with tissue-penetrating nanotherapy","volume":"14","author":"Sidorenko","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.canlet.2026.218824_bib189","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s12951-021-00865-w","article-title":"Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma","volume":"19","author":"Zhao","year":"2021","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.canlet.2026.218824_bib190","doi-asserted-by":"crossref","first-page":"4778","DOI":"10.3390\/ijms21134778","article-title":"Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents","volume":"21","author":"Horsman","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib191","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/cbdd.13166","article-title":"An overview on vadimezan (DMXAA): the vascular disrupting agent","volume":"91","author":"Daei Farshchi Adli","year":"2018","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.canlet.2026.218824_bib192","article-title":"Anti-angiogenic therapy enhances cancer immunotherapy: mechanism and clinical application","volume":"2","author":"Li","year":"2024","journal-title":"Interdiscip. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib193","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s00262-022-03318-x","article-title":"Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model","volume":"72","author":"Qiao","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218824_bib194","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/nrd.2015.35","article-title":"Development of immuno-oncology drugs \u2014 from CTLA4 to PD1 to the next generations","volume":"15","author":"Hoos","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.canlet.2026.218824_bib195","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib196","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.3390\/cancers13061440","article-title":"CTLA-4 in regulatory T cells for cancer immunotherapy","volume":"13","author":"Sobhani","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.canlet.2026.218824_bib197","article-title":"Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade","volume":"6","author":"Blanchard","year":"2025","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib198","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1158\/0008-5472.CAN-17-2176","article-title":"Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer","volume":"78","author":"Meder","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2026.218824_bib199","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41416-023-02519-0","article-title":"A phase Ib\/II study of cadonilimab (PD-1\/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer","volume":"130","author":"Chen","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib200","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.canlet.2026.218824_bib272","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib273","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1056\/NEJMoa1716948","article-title":"Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC","volume":"378","author":"Socinski","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib274","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1016\/S0140-6736(19)30723-8","article-title":"Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial","volume":"393","author":"Rini","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2026.218824_bib275","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1056\/NEJMoa2108330","article-title":"Lenvatinib plus pembrolizumab for advanced endometrial cancer","volume":"386","author":"Makker","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib276","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib277","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/S0090-8258(22)01243-4","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer: a cost-effectiveness analysis","volume":"166","author":"Barrington","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib278","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib279","article-title":"Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN renal 101","volume":"7","author":"Tomita","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.canlet.2026.218824_bib280","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib201","first-page":"93","article-title":"Neoantigen therapeutic cancer vaccines: a promising approach to personalized immunotherapy","volume":"13","author":"Pobo\u017cy","year":"2023","journal-title":"OncoReview"},{"key":"10.1016\/j.canlet.2026.218824_bib202","doi-asserted-by":"crossref","DOI":"10.2217\/cns-2018-0009","article-title":"Phase II study of ERC1671 plus bevacizumab versus bevacizumab plus placebo in recurrent glioblastoma: interim results and correlations with CD4+ T-lymphocyte counts","volume":"7","author":"Bota","year":"2018","journal-title":"CNS Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib203","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/cncr.21956","article-title":"Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy","volume":"107","author":"Rini","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib204","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aao5931","article-title":"Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer","volume":"10","author":"Tanyi","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib205","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112512","article-title":"Therapeutic potential of CAR T cell in malignancies: a scoping review","volume":"146","author":"Mehrabadi","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.canlet.2026.218824_bib206","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFRvIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218824_bib207","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/mt.2011.39","article-title":"Sequential therapy with JX-594, a targeted oncolytic poxvirus, followed by sorafenib in hepatocellular carcinoma: preclinical and clinical demonstration of combination efficacy","volume":"19","author":"Heo","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.canlet.2026.218824_bib208","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib209","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw026","article-title":"miR-141-mediated regulation of brain metastasis from breast cancer","volume":"108","author":"Debeb","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.canlet.2026.218824_bib210","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.canlet.2026.218824_bib211","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib212","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.jhep.2021.11.030","article-title":"Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma","volume":"76","author":"Cheng","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.canlet.2026.218824_bib213","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S1470-2045(23)00469-2","article-title":"Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial","volume":"24","author":"Llovet","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib214","doi-asserted-by":"crossref","DOI":"10.3390\/ijms262010085","article-title":"Vascular disruption therapy as a new strategy for cancer treatment","volume":"26","author":"G\u00f3mez-Escudero","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218824_bib215","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma","volume":"24","author":"McDermott","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218824_bib216","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade","volume":"38","author":"Motzer","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2026.218824_bib217","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib218","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1093\/annonc\/mdx767","article-title":"Analysis of angiogenesis biomarkers for ramucirumab efficacy in patients with metastatic colorectal cancer from RAISE, a global, randomized, double-blind, phase III study","volume":"29","author":"Tabernero","year":"2018","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218824_bib219","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1080\/03007995.2021.1940908","article-title":"Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study","volume":"37","author":"Taniguchi","year":"2021","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.canlet.2026.218824_bib220","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1158\/0008-5472.CAN-09-0814","article-title":"A \u201cvascular normalization index\u201d as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients","volume":"69","author":"Sorensen","year":"2009","journal-title":"Cancer Res."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526005884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:22:07Z","timestamp":1791339727000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526005884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":280,"alternative-id":["S0304383526005884"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218824","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Revisiting tumor vasculature in the era of cancer immunotherapy: from aberrant hallmark to therapeutic target","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218824","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"218824"}}